For the better-seeing eyes at baseline , the mean change in composite score with 0.3 mg ranibizumab at the 24-month visit was 10.9 more ( 95 % confidence interval [ CI ] , 2.5-19 .2 ) than sham for RIDE patients and 1.3 more ( 95 % CI,-10 .5 to 13.0 ) than sham for RISE patients .